FAST Study and SUGAR Trial findings: Robertson Centre research updates
Published: 28 June 2018
IHW's Robertson Centre for Biostatistics updates us on recent research findings
IHW's Robertson Centre for Biostatistics updates us on recent research findings
FAST Study
Researchers from the Robertson Centre for Biostatistics, along with researchers in Dundee and Edinburgh, led a major new study examining the relative safety of medicines for the treatment of gout.
The FAST Study found no increased risk of cardiovascular events with febuxostat as compared with allopurinol.
The results were published in the Lancet.
SUGAR Trial
Researchers from IHW (RCB) and ICAMS and have furthered the understanding of how novel diabetes drugs can improve prognosis for patients with heart failure. The results of the SUGAR-DM-HF trial showed that the drug empagliflozin, originally a treatment for patients with type 2 diabetes, was able to significantly reduce the size of abnormally large hearts, which helps explain how they reduce the risk of hospitalisation and cardiovascular death in patients with heart failure.
The results were published in Circulation and presented to the American Heart Association.
First published: 28 June 2018